Crossmark

Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study

Crossref DOI link: https://doi.org/10.1186/s12885-024-12831-4

Published Online: 2024-09-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cheng, Yu

Teng, Zan

Zhang, Yanqiao

Jin, Bo

Zheng, Zhendong

Man, Li

Wang, Zhenghua

Teng, Yuee

Yu, Ping

Shi, Jing

Luo, Ying

Wang, Ying

Zhang, Jingdong

Zhang, Huijuan

Liu, Jiwei

Chen, Hao

Xiao, Jiawen

Zhao, Lei

Zhang, Lingyun

Jiang, Yu

Chen, Ying

Zhang, Jian

Wang, Chang

Liu, Sa

Qu, Jinglei

Qu, Xiujuan

Liu, Yunpeng
License Information

Text and Data Mining valid from 2024-09-02

Version of Record valid from 2024-09-02
More Information

Article History

Received: 22 January 2024

Accepted: 20 August 2024

First Online: 2 September 2024

Declarations

:

: This clinical study was approved by Committee of Clinical Trials of The First Hospital of China Medical University. Informed consent was obtained from all subjects and/or their legal guardian(s). The study was performed in accordance with the Declaration of Helsinki.

: Not Applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below